Biotechnology and Biomaterial-Based Therapeutic Strategies for Age-Related Macular Degeneration. Part II: Cell and Tissue Engineering Therapies

Jemni Damer, Nahla, Guedan Duran, Atocha, Fuentes Andion, Maria, Serrano Bengoechea, Nora, Alfageme Lopez, Nuria, Armada Maresca, Felix, Guinea Tortuero, Gustavo Víctor ORCID: https://orcid.org/0000-0002-4326-3746, Pérez Rigueiro, José ORCID: https://orcid.org/0000-0001-8298-8398, Rojo Pérez, Francisco Javier ORCID: https://orcid.org/0000-0001-9517-0050, González Nieto, Daniel ORCID: https://orcid.org/0000-0003-2972-729X, Kaplan, David L. and Panetsos, Fivos ORCID: https://orcid.org/0000-0003-0897-411X (2020). Biotechnology and Biomaterial-Based Therapeutic Strategies for Age-Related Macular Degeneration. Part II: Cell and Tissue Engineering Therapies. "Frontiers in Bioengineering and Biotechnology", v. 8 ; ISSN 2296-4185. https://doi.org/10.3389/fbioe.2020.588014.

Descripción

Título: Biotechnology and Biomaterial-Based Therapeutic Strategies for Age-Related Macular Degeneration. Part II: Cell and Tissue Engineering Therapies
Autor/es:
Tipo de Documento: Artículo
Título de Revista/Publicación: Frontiers in Bioengineering and Biotechnology
Fecha: Diciembre 2020
ISSN: 2296-4185
Volumen: 8
Materias:
ODS:
Palabras Clave Informales: retinal pigment epithelium; Bruch’ s membrane; photoreceptors; biomaterials; cell therapy; tissue engineering; biotechnology; cell replacement
Escuela: Centro de Tecnología Biomédica (CTB) (UPM)
Departamento: Ciencia de los Materiales
Grupo Investigación UPM: Materiales Estructurales Avanzados y Nanomateriales
Licencias Creative Commons: Ninguna

Texto completo

[thumbnail of 77744.pdf] PDF (Portable Document Format) - Se necesita un visor de ficheros PDF, como GSview, Xpdf o Adobe Acrobat Reader
Descargar (1MB)

Resumen

Age-related Macular Degeneration (AMD) is an up-to-date untreatable chronic neurodegenerative eye disease of multifactorial origin, and the main causes of blindness in over 65 y.o. people. It is characterized by a slow progression and the presence of a multitude of factors, highlighting those related to diet, genetic heritage and environmental conditions, present throughout each of the stages of the illness. Current therapeutic approaches, mainly consisting on intraocular drug delivery, are only used for symptoms relief and/or to decelerate the progression of the disease. Furthermore, they are overly simplistic and ignore the complexity of the disease and the enormous differences in the symptomatology between patients. Due to the wide impact of the AMD and the up-to-date absence of clinical solutions, Due to the wide impact of the AMD and the up-to-date absence of clinical solutions, different treatment options have to be considered. Cell therapy is a very promising alternative to drug-based approaches for AMD treatment. Cells delivered to the affected tissue as a suspension have shown poor retention and low survival rate. A solution to these inconveniences has been the encapsulation of these cells on biomaterials, which contrive to their protection, gives them support, and favor their retention of the desired area. We offer a two-papers critical review of the available and under development AMD therapeutic approaches, from a biomaterials and biotechnological point of view. We highlight benefits and limitations and we forecast forthcoming alternatives based on novel biomaterials and biotechnology methods. In this second part we review the preclinical and clinical cell-replacement approaches aiming at the development of efficient AMD-therapies, the employed cell types, as well as the cell-encapsulation and cell-implant systems. We discuss their advantages and disadvantages and how they could improve the survival and integration of the implanted cells.

Proyectos asociados

Tipo
Código
Acrónimo
Responsable
Título
Gobierno de España
MAT2016-76847-R
Sin especificar
Sin especificar
Sin especificar
Gobierno de España
MAT2015-66666-C3-3-R
Sin especificar
Sin especificar
Sin especificar
Gobierno de España
MAT2016-79832-R
Sin especificar
Sin especificar
Sin especificar
Comunidad de Madrid
B2017/BrMD-3760
Sin especificar
Sin especificar
Sin especificar
Comunidad de Madrid
IND2018/BrMD-9804
Sin especificar
Sin especificar
Sin especificar

Más información

ID de Registro: 77744
Identificador DC: https://oa.upm.es/77744/
Identificador OAI: oai:oa.upm.es:77744
Identificador DOI: 10.3389/fbioe.2020.588014
URL Oficial: https://www.frontiersin.org/articles/10.3389/fbioe...
Depositado por: Prof. Dr. Gustavo Guinea
Depositado el: 27 Ene 2024 18:10
Ultima Modificación: 27 Ene 2024 18:10